Antimicrobial Resistance Rates and Surveillance in Sub-Saharan Africa: Where Are We Now?
Open accessThe DOI matches its Crossref record; 190 of the 190 references it cites were found in a registry or an index; 74 of the 94 sources its claims cite were checked for support.
Abstract
Introduction: Although antimicrobials have traditionally been used to treat infections and improve health outcomes, resistance to commonly used antimicrobials has posed a major challenge. An estimated 700,000 deaths occur globally every year as a result of infections caused by antimicrobial-resistant pathogens. Antimicrobial resistance (AMR) also contributes directly to the decline in the global economy. In 2019, sub-Saharan Africa (SSA) had the highest mortality rate (23.5 deaths per 100,000) attributable to AMR compared to other regions. Methods: We searched PubMed for articles relevant to AMR in pathogens in the WHO-GLASS list and in other infections of local importance in SSA. In this review, we focused on AMR rates and surveillance of AMR for these priority pathogens and some of the most encountered pathogens of public health significance. In addition, we reviewed the implementation of national action plans to mitigate against AMR in countries in SSA. Results and Discussion: The SSA region is disproportionately affected by AMR, in part owing to the prevailing high levels of poverty, which result in a high burden of infectious diseases, poor regulation of antimicrobial use, and a lack of alternatives to ineffective antimicrobials. The global action plan as a strategy for prevention and combating AMR has been adopted by most countries, but fewer countries are able to fully implement country-specific action plans, and several challenges exist in many settings. Conclusion: A concerted One Health approach will be required to ramp up implementation of action plans in the region. In addition to AMR surveillance, effective implementation of infection prevention and control, water, sanitation, and hygiene, and antimicrobial stewardship programs will be key cost-effective strategies in helping to tackle AMR.
Overview
CoChat Summary
TL;DR
This review summarizes antimicrobial resistance rates among WHO-GLASS and locally important pathogens in sub-Saharan Africa and assesses national action plan implementation. It reports that SSA has the highest AMR-attributable mortality and that NAP implementation remains limited by funding, surveillance, and multisectoral coordination gaps.
Key findings
- In 2019, SSA had the highest AMR-attributable mortality rate (23.5 deaths per 100,000), with Western SSA highest at 27.3 deaths per 100,000; globally, 4.95 million deaths were associated with AMR and 1.27 million were attributable to AMR.
- Resistance was widespread among reviewed pathogens: diarrheagenic E. coli prevalence ranged from 14.7% to 82%; multidrug-resistant S. Typhi subclade 4.3.1 prevalence ranged from 60.4% to 97%; MRSA prevalence ranged from 1.25% to 53.4%; carbapenem-resistant P. aeruginosa prevalence ranged from 6% to 34.8%; and East Africa had the highest A. baumannii carbapenem resistance prevalence at 23%.
- NAP implementation was limited: 11 (25%) of 44 SSA countries had NAPs on AMR; 32% performed routine AMR surveillance on clinical pathogens and 2% on veterinary pathogens; 59% had a dedicated National Reference Laboratory; by February 2022, 15 SSA countries had fully developed NAPs. Thematic performance was 38±12% for awareness creation and training, 18±13% for surveillance, 33±13% for infection prevention and control, 28±23% for optimal antimicrobial use, and 59±12% for multisector and One Health collaboration.
- Burden estimates included 141,918 cholera infections per year in SSA; approximately 1.5 million typhoid cases and 19,900 deaths annually in SSA, accounting for about 17% of global typhoid deaths; 421,600 invasive non-typhoidal Salmonella cases and 66,520 deaths in SSA; and 31% of neonatal sepsis mortalities (690,000) plausibly attributed to antimicrobial-resistant infections.
Methods
- Narrative review of English original articles and reviews retrieved from PubMed and Google Scholar, covering the WHO-Africa region divided into Western, Eastern, Central, and Southern SSA; search terms included antimicrobial resistance, multi-drug resistance, sub-Saharan Africa, surveillance, global action plan, national action plan, and One Health approach; articles published between 2000 and 2022 were considered.
- Pathogens were selected as WHO-GLASS priority pathogens plus Vibrio cholerae; inclusion criteria covered articles on selected pathogens from SSA countries, articles reporting antibiotic resistance rates and genes, and both monomicrobial and polymicrobial studies; exclusions were non-WHO-GLASS pathogens, articles from beyond SSA, conference abstracts, intervention trials, and duplicates.
- The review presents resistance rates from cited studies in tables and discusses NAP implementation; it does not report a pooled meta-analysis.
Limitations
- The paper states that precise burden estimates for resistant K. pneumoniae in SSA are lacking and that available data are generated in referral/research/university hospitals, which do not represent the broad range of healthcare settings; it also states that few A. baumannii reports come from low-income countries, making prevalence estimates difficult.
- The paper states that the paucity of data in SSA on AMR prevalence and antimicrobial use is a major impediment, and it lists NAP implementation challenges including inadequate funding, poor coordination, inadequate surveillance data, poor infrastructure and health systems, staffing shortages, and lack of monitoring and quality assurance systems.
- Evident from the text: as a narrative review using PubMed/Google Scholar and heterogeneous published studies, resistance rates are not pooled or systematically appraised, and many estimates come from single-center or referral-hospital studies that may not be generalizable.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
50 Valid · 5 Not valid · 14 Not checked · 32 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In 2019, sub-Saharan Africa (SSA) had the highest mortality rate (23.5 deaths per 100,000) attributable to AMR compared to other regions.”
- Also stated in: § Impact of Antimicrobial Resistance · plain
“Compared to other Global Burden of Disease study regions, sub-Saharan Africa (SSA) and South Asia had the highest mortalities (23.5 deaths per 100,000 and 21.5 deaths per 100,000, respectively) attributable to AMR.”
§ Antimicrobial Resistance Rates and Surveillance in Sub-Saharan Africa: Where Are We Now? > Abstract
What the sources say
- Partly supportedcites [8] Murray, 2022, Lancet sourceExperimental — accuracy not yet measured
The Results report that sub-Saharan Africa had the highest all-age death rate attributable to AMR in 2019. However, they give 27.3 deaths per 100,000 for western sub-Saharan Africa, the highest of the 21 regions; our copy does not substantiate the claimed 23.5 deaths per 100,000 for sub-Saharan Africa as a whole. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Impact of Antimicrobial Resistance · plain
Every source the paper cites for this claim was checked and supports it.
In the paper
“Indeed, the rapid emergence of antimicrobial-resistant pathogens is often accelerated by the inappropriate use and overuse of antimicrobial agents, especially antibiotics, in humans, animals, and agriculture/the environment.”
§ Antimicrobial Resistance Rates and Surveillance in Sub-Saharan Africa: Where Are We Now? > Role of Antimicrobial Use in Increasing Rates of AMR
What the sources say
- Supportedcites [18] Sartelli, 2020, Antibiotics source
Section 2, “Antimicrobial Resistance: A Global Challenge,” says antibiotic use, misuse and abuse in human, animal and environmental sectors drive AMR, and that misuse selects resistant microorganisms. Section 3, “Antimicrobial Resistance in LMICs,” also identifies antibiotic use in agriculture as a challenge. (LLM, conf=0.94)
- Supportedcites [19] Van, 2020, J Glob Antimicrob Resist source
The Introduction identifies repeated antibiotic use in food animals as a significant contributor to antimicrobial resistance and acknowledges the contribution of misuse in humans. Section 4 says widespread antibiotic use in animals accelerates the emergence of resistance and describes the environment as a reservoir and route of spread, including antibiotic use in aquaculture. (LLM, conf=0.90)
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In neonatal sepsis, 31% of mortalities (690,000) reported were plausibly attributed to antimicrobial-resistant infections.”
§ Antimicrobial Resistance Rates and Surveillance in Sub-Saharan Africa: Where Are We Now? > Impact of Antimicrobial Resistance
What the sources say
- Supportedcites [11] Li, 2020, Arch Dis Child source
The Introduction reports a previous estimate that 214,000 of 690,000 annual neonatal deaths associated with sepsis (31%) were potentially attributable to antimicrobial resistance. The paper presents this as an estimate from Laxminarayan et al., not a finding of the NeoAMR study. (LLM, conf=0.91)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The study found that the consumption rate increased from 9.8 (9.2-10.5)daily defined doses (DDD) to 14.3 (13.2-15.6)DDD per 1000 population per day.”
§ Antimicrobial Resistance Rates and Surveillance in Sub-Saharan Africa: Where Are We Now? > Role of Antimicrobial Use in Increasing Rates of AMR
What the sources say
- Supportedcites [26] Browne, 2021, Lancet Planetary Health source
The Results report that global antibiotic consumption rose from 9.8 (95% uncertainty interval 9.2–10.5) to 14.3 (13.2–15.6) defined daily doses per 1000 people per day between 2000 and 2018. These are the figures and period attributed to the study. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A study published in 2021 reported that there was a 46% increase in the global consumption of antimicrobials between 2000 and 2018.”
§ Antimicrobial Resistance Rates and Surveillance in Sub-Saharan Africa: Where Are We Now? > Role of Antimicrobial Use in Increasing Rates of AMR
What the sources say
- Partly supportedcites [26] Browne, 2021, Lancet Planetary Health sourceExperimental — accuracy not yet measured
The Introduction (Added value of this study) reports a 46% increase in global antibiotic consumption since 2000, and the Results give the 2000 and 2018 consumption rates. The study measures antibiotics, not antimicrobials as a whole, so the claim broadens its scope. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
38 more claims · 18 with their cited sources checked
Create a free account to see all 101 claims and to verify the 4 references still open.
- Probably not a substantial claim. 27
- It may state two separate claims as one. 42
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Such sparsity is mainly due to insufficient laboratory infrastructure and capacity, scarce or absent microbiological facilities, weak health systems and governance and information systems, and scarce resources.60, 72, 73”
From Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050 (2024) · cites this paper as [73]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Antimicrobial Resistance Rates and Surveillance in Sub-Saharan Africa: Where Are We Now? > Carbapenem-Resistant Acinetobacter baumannii
“Out of the 29 countries, only 16 countries reported the detection of A. baumannii within their territories at least once in the last 21 years.”
§ Antimicrobial Resistance Rates and Surveillance in Sub-Saharan Africa: Where Are We Now? > Carbapenem-Resistant Acinetobacter baumannii
“Accordingly, 11 out of the 29 have no A. baumannii reports at all in the three searched databases.”
Citations
Cites
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis
Murray, C. J. L., Ikuta, K. S., Sharara, F., Swetschinski, L., Robles Aguilar, G., Gray, A., Han, C., Bisignano, C., Rao, P., Wool, E., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02724-0 · Cited by 16,316 · cited 2×
“aeruginosa accounting for 38,100 deaths globally.(151) The prevalence of carbapenem-resistant P.”
BackgroundTacconelli, E., Carrara, E., Savoldi, A., Harbarth, S., Mendelson, M., Monnet, D. L., Pulcini, C., Kahlmeter, G., Kluytmans, J., Carmeli, Y., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30753-3 · Cited by 6,142 · cited 2×
“aeruginosa as one of the three critical global priority pathogens that require development of new antibiotics.(144) It is estimated that in 2019, antimicrobialresistant P.”
BackgroundAcinetobacter baumannii : Emergence of a Successful Pathogen
Peleg, A. Y., Seifert, H., & Paterson, D. L. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00058-07 · Cited by 3,316 · cited 1×
“Acinetobacter baumannii is often implicated in bloodstream, urinary tract, pneumonia, skin and soft tissue infections, and meningitis.(138,139) Owing to its AMR,(140) A.”
BackgroundAntibiotic resistance in the environment
Larsson, D. G. J., & Flach, C.-F. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00649-x · Cited by 3,164
Cassini, A., Högberg, L. D., Plachouras, D., Quattrocchi, A., Hoxha, A., Simonsen, G. S., Colomb-Cotinat, M., Kretzschmar, M. E., Devleesschauwer, B., Cecchini, M., et al. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30605-4 · Cited by 2,945 · cited 1×
“conducted in the European Union, published in 2019, estimates an annual number of disability-adjusted life-years (DALYs) at 148,727 (131,757–166,361) per 1,000,000 population, infections at 112,782 (103,186–122,006), and attributable deaths at 6810 (6096–7559).(156) While surveillance systems are in place in developed…”
BackgroundAntimicrobial Resistance: Implications and Costs
Dadgostar, P. (2019) · Infection and Drug Resistance · doi:10.2147/idr.s234610 · Cited by 2,024 · cited 1×
“Infections caused by antimicrobial-resistant pathogens are reported to result in approximately 700,000 deaths globally every year.(3)”
BackgroundManyi-Loh, C., Mamphweli, S., Meyer, E., & Okoh, A. (2018) · Molecules · doi:10.3390/molecules23040795 · Cited by 1,808 · cited 19×
“Some of the challenges that hinder the implementation of NAPs are: 1) a lack of political commitment, 2) inadequate funding, 3) poor coordination and collaboration between the different sectors, 4) inadequate surveillance Infection and Drug Resistance 2022:15 https://doi.org/10.2147/IDR.S342753 DovePress 3601 Powered…”
BackgroundInfluentialTroeger, C., Blacker, B. F., Khalil, I. A., Rao, P. C., Cao, S., Zimsen, S. R., Albertson, S. B., Stanaway, J. D., Deshpande, A., Abebe, Z., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30362-1 · Cited by 1,476 · cited 1×
“According to the 2016 Global Burden of Disease (GBD) report, cumulatively these two pathotypes result in 63,523 deaths among all ages annually, throughout the world.(36) Other important E.”
BackgroundThe threat of antimicrobial resistance in developing countries: causes and control strategies
Ayukekbong, J. A., Ntemgwa, M., & Atabe, A. N. (2017) · Antimicrobial Resistance & Infection Control · doi:10.1186/s13756-017-0208-x · Cited by 1,315 · cited 17×
“Some of the challenges that hinder the implementation of NAPs are: 1) a lack of political commitment, 2) inadequate funding, 3) poor coordination and collaboration between the different sectors, 4) inadequate surveillance Infection and Drug Resistance 2022:15 https://doi.org/10.2147/IDR.S342753 DovePress 3601 Powered…”
BackgroundInfluentialHealth systems financing and the path to universal coverage
Evans, D. B., & Etienne, C. (2010) · Bulletin of the World Health Organization · doi:10.2471/blt.10.078741 · Cited by 1,279
Research works printed but not linked: 6
- 2014, Estimating the Economic Costs of Antimicrobial Resistance
- Webale, 2020, Gastroenterol Hepatol Bed Bench, 13, 238
- Kanteh, 2021, Microb Genom, 7, 000677
- Cornick, 2021, Microb Genom, 7, 000703
- 2022, StatPearls
- Murray, 2022, Lancet, 399, 629, 10.1016/S0140-6736(21)02724-0 · DOI · Paper page
Cited by
Items 101–200 of 235
Kavulavu, B. M., Omwenga, E. O., Nyangiri, O. A., Nyerere, A. K., Too, R. J., Matey, E. J., Goepel, S., Mogoa, W., Schilling, T., Hoelzle, L. E., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0331389 · Cited by 7
“Studies conducted in SSA demonstrate that resistance rates among Enterobacterales isolates are alarmingly high, with resistance to first-line [12,19] and even last-resort antibiotics increasingly documented both in clinical and environmental sources [12, 19–21].”
Nale, J. Y., Chan, B. K., Nnadi, N. E., Cheng, J. K. J., Matts, S., Nezam-Abadi, N., Turkington, C. J. R., Charreton, L. M., Bola, H., Nazir, R., et al. (2023) · PHAGE · doi:10.1089/phage.2023.0012 · Cited by 5
Sharma, H. K., Singh, R., Grover, A., Malik, R., Triveni, T., Singh, S., Lather, V., & Vijay, N. (2025) · Infectious diseases · doi:10.5772/intechopen.1012085 · Cited by 4
Maitreyi, L., & Sambandamurthy, V. K. (2025) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.5c00565 · Cited by 5
Mudenda, S., Chizimu, J. Y., Daka, V., Kasanga, M., Mufwambi, W., Mwangilwa, K., Hangoma, J. M., Gardner, P. N., Chileshe, C., Mudenda, N. B., et al. (2025) · Antibiotics · doi:10.3390/antibiotics14111126 · Cited by 5
“Zambia, like many low-and middle-income countries (LMICs), faces significant challenges in addressing AMR due to weak regulation and enforcement of AMU, limited access to quality medicines, and critical gaps in surveillance data [64–66].”
Mba, I. E., & Martins, F. T. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1714021 · Cited by 4
“In 2019 alone, the region recorded approximately 27.3 AMR-related deaths per 100,000 population, compared to 6.3 per 100,000 in high-income countries (Kariuki et al., 2022; Africa CDC, 2024).”
InfluentialBridging the bioinformatics gap: tool selection for decentralized AMR genomic surveillance in Africa
Lacy-Roberts, N., Gibson, C. T., Nilsson, P., Weese, C. J., Odgaard, C., Thornval, N. R., & Hendriksen, R. S. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1756324 · Cited by 5
Sustainably addressing Africa’s antimicrobial pollution crisis
Barasa, S. S., Ntie‐Kang, F., Wambu, E. W., Metuge, J. A., Kedi, P. B. E., Amewu, R. K., Shadrack, D. M., Barasa, D. T., Omara, T., & Mwasi, B. N. (2024) · Nature Reviews Earth & Environment · doi:10.1038/s43017-024-00618-x · Cited by 4
Kusuma, I. Y., Octaviani, P., Nurkholis, F., Prabandari, R., Derek, R., & Sariati, Y. (2025) · BIO Web of Conferences · doi:10.1051/bioconf/202515201003 · Cited by 4
“The GLASS program's focus on antimicrobial resistance is only one part of the Member States' efforts to improve health security, strengthen health systems, and ensure universal health care throughout Africa [56].”
Munzhedzi, M., Kumar, S., Godman, B., & Meyer, J. C. (2025) · Advances in Human Biology · doi:10.4103/aihb.aihb_132_25 · Cited by 7
Delpy, L. (2025) · Climate and Development · doi:10.1080/17565529.2025.2498145 · Cited by 3
“Linked to the overuse or misuse, antimicrobials resistance is also driven by transmission between livestock, wild animals, human populations and environment (Kariuki et al., 2022; McEwen & Collignon, 2018).”
Mbwasi, R., Omolo, C. A., Ombaka, E., Kingo, R. M., Mbugua, S. M., & Wiedenmayer, K. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-096682 · Cited by 3
Poignon, C., Dortet, L., Birer, A., Rezzoug, I., Emeraud, C., Girlich, D., Naas, T., Bonnin, R. A., & Jousset, A. B. (2025) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaf206 · Cited by 3
Manirakiza, A., Maru, S. M., Nyamu, D. G., Bizimana, T., & Nimpagaritse, M. (2025) · BMC Family Practice · doi:10.1186/s12875-025-02944-5 · Cited by 3
“Furthermore, a systematic analysis ( 1995– 2015) In comparison with other global burden regions, sub-Saharan Africa and South Asia were found to have the highest rates of deaths due to antimicrobial resistance (AMR), with 23.5 deaths per 100,000 people and 21.5 deaths per 100,000, respectively [15].”
InfluentialAluvilu, A. N., Fuller, W. L., Erastus, A. N., Busch, F., Dreyer, S., Anderson, L.-M., & Nabyonga‐Orem, J. (2025) · Journal of Global Health · doi:10.7189/jogh.15.04294 · Cited by 3
Mcharo, O., Kapesa, A., Materu, J., Luwayi, J. R., Nahay, F., Basinda, N., Chibwe, E., & Okello, E. S. (2025) · Reproductive Health · doi:10.1186/s12978-025-02087-x · Cited by 4
Global Burden and Trends of Invasive Non-Typhoidal Salmonella Infection from 1990 to 2021
Meng, Z., Song, T., Chen, J., Zhang, X., Zhao, X., Ling, J., Wen, H., Qiu, Y., Tian, X., Wu, J., et al. (2025) · Foodborne Pathogens and Disease · doi:10.1177/15353141251398051 · Cited by 6
Addressing infectious diseases in Africa by accelerating drug discovery through data science
Turón, G., Hlozek, J., Duran‐Frigola, M., Chibale, K., & Woodland, J. G. (2025) · Communications Medicine · doi:10.1038/s43856-025-01211-z · Cited by 3
“In 2019, the sub-Saharan Africa region harboured the highest burden of antimicrobial resistance-related deaths at 23.5 deaths per 100,000 inhabitants compared to other regions 10 .”
InfluentialFaiela, C., Cambaço, O., Boene, H. E., Monnier, A. A., Wertheim, H. F. L., Munguambe, K., & Sevene, E. (2025) · Scientific Reports · doi:10.1038/s41598-025-99030-8 · Cited by 3
“This is exacerbated in low-income countries, where the global burden of infectious diseases is the highest in sub-Saharan Africa in particular, where the relative number of deaths attributed to antimicrobial resistance is higher than in other parts of the world 6 .”
The Role of Pseudomonas aeruginosa in Surgical Site Infections in Sub-Saharan Africa
Kindiki, S., Nyongesa, P. K., Mogoi, N. N., & Kiprono, S. J. (2025) · Science Mundi · doi:10.51867/scimundi.5.1.2 · Cited by 3
“…the commonly used antibiotics in the region including fluoroquinolones, beta-lactams, and aminoglycosides (Ntirenganya et al., 2015; Tadesse et al., 2017; Kariuki et al., 2022; Moyo et al., 2023), limit the available treatment options which further pose a major challenge in line with patient care.”
Sanke‐Waîgana, H., Fall, C., Gody, J., Komba, E. K., Ngaya, G., Mbecko, J., Yambiyo, B. M., Manirakiza, A., Vernet, G., Dièye, A., et al. (2023) · Bacteria · doi:10.3390/bacteria2010005 · Cited by 3
Mwailunga, H. A., Katemi, E. S., Niccodem, E. M., & Matee, M. I. (2023) · German Journal of Microbiology · doi:10.51585/gjm.2023.3.0025 · Cited by 3
Garoy, E. Y., Ghebrehiwet, M. A., Fessehaye, N., Achila, O. O., Gebrehiwet, G. Y., Abraham, F. G., Berhe, S. D., Berhe, Y. L., Mengistu, S. T., Buthuamlak, A. M., et al. (2026) · BMC Infectious Diseases · doi:10.1186/s12879-026-12518-0 · Cited by 3
“Beyond prescribing habits, other drivers include poor hospital waste management, inadequate hand hygiene, contaminated medical equipment, lack of infection control infrastructure, and overcrowding in wards and hospices [38].”
Iwu, C. J., Gahimbare, L., Mazengiya, Y. D., Okeibunor, J., Olu, O. O., Jaca, A., Mazingisa, A. V., Iwu, C. D., Yahaya, A. A., & Wiysonge, C. S. (2026) · BMJ Public Health · doi:10.1136/bmjph-2025-004853 · Cited by 3
“Research output is also geographically concentrated in a small number of countries, leaving much of the Region under-represented and limiting the transferability of current evidence.”
Neuerer, M., Baxerres, C., Dekker, D. M., Bila, B., Arhinful, D. K., Aglanu, L. M., Akenten, C. W., Coulibaly, B., Sié, A., Amuasi, J., et al. (2025) · JMIR Research Protocols · doi:10.2196/66424 · Cited by 2
“In addition, a One Health approach should be implemented in future studies to develop efficient interventions on AMR and improve AMR surveillance and control in Africa [19,20].”
Munene, A. K., Majiwa, H., & Bukusi, E. (2024) · Journal of Heart and Vasculature · doi:10.31579/2834-8788/022 · Cited by 3
Reigada, I., Togbé, E., Sovègnon, T., Ylätalo, M., Kapp, K., Zore, M., Sipari, N., Legba, B. B., Dougnon, V. T., & Hanski, L. L. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.120434 · Cited by 2
Azithromycin resistance in nontyphoidal Salmonella in an urban informal settlement in Nairobi, Kenya
Kering, K., Njaanake, K. H., Wairimu, C., Mureithi, M., Kebenei, C. K., Mbae, C. K., Mugo, M., Kavai, S. M., Kibet, E., Mbithi, W., et al. (2025) · Microbiology Spectrum · doi:10.1128/spectrum.00985-25 · Cited by 3
“Several studies have reported on MDR NTS in SSA (17), including in Kenya (3, 4), Mozambique (18), Malawi (19, 20), Nigeria (21), and the Democratic Republic of Congo (22), with a high proportion of the MDR NTS being S .”
InfluentialSelf-citationHaindongo, E., Hakanen, A., Vainio, O., Vuopio, J., & Hedimbi, M. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-12186-6 · Cited by 2
“Strengthening surveillance systems is recognized as one of the key strategies in combating AMR [6–8].”
Leveraging a people-centred approach to combat antimicrobial resistance in Africa
Adebisi, Y. A., Akande‐Sholabi, W., Jimoh, N. D., Lali, H., Adebowale, K. A., Ouachhou, A., Egwu, K. C., Nachibwede, L. V., Shomuyiwa, D. O., Gilbert, A., et al. (2025) · Tropical Medicine and Health · doi:10.1186/s41182-025-00863-w · Cited by 2
“While investing in infrastructure that supports accurate diagnosis is key to reducing AMR in these regions [42], the financial and political realities cannot be ignored.”
Paul, S., Sarkar, A., Ghosh, M., Datta, D., Debnath, M., Basak, S., Raychaudhuri, S., & Bhattacharjee, S. (2025) · 3 Biotech · doi:10.1007/s13205-025-04621-x · Cited by 4
“The rise of cholera cases and the antimicrobial-resistant Vibrio cholerae strains in some regions especially Africa, South East Asia, the Middle East, and South America, poses a significant threat to effective cholera treatment and con - trol (Kariuki et al. 2022; Mushanyu et al. 2024).”
The supply chain lens of the burden of antimicrobial resistance in Sub-Saharan Africa
Olpengs, D., Munjuri, A. K., Benson, A. E., Othman, Z. K., & Adebisi, Y. A. (2025) · Discover Public Health · doi:10.1186/s12982-025-01242-w · Cited by 2
“Sub-Saharan Africa (SSA) presents the highest rates of 23.5 deaths per 100,000 globally with western SSA having the highest death rate followed by Eastern, Central, and Southern SSA [1].”
InfluentialDetchaptche, S. P. N., Jain, S., Mahdi, A., Gandra, S., & Sulis, G. (2026) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2026.2625376 · Cited by 3
Shimber, E. T., Teferi, M. G., Aweke, K. W., Zemede, B., & Hassen, G. W. (2026) · IJID Regions · doi:10.1016/j.ijregi.2026.100866 · Cited by 2
“Limited clinical microbiology infrastructure, particularly at district and secondary healthcare levels, continues to constrain the coverage, representativeness, and clinical utility of national AMR surveillance systems [ 9 ].”
Azour, A., Matar, G. M., & Bilen, M. (2026) · BMC Microbiology · doi:10.1186/s12866-026-04791-5 · Cited by 3
“…Georgia, Niger, Afghanistan, Cambodia, Democratic Republic of the Congo, Morocco, Switzerland, Mongolia, Singapore, Turkey, Pakistan, Thailand, Spain, and Libya, also displayed substantial normalized ARG burdens, highlighting pronounced regional differences in resistome composition [36–38].”
Magesa, B., Mwelange, L. P., Sirili, N. S., & Mhame, M. (2026) · PLOS Global Public Health · doi:10.1371/journal.pgph.0006123 · Cited by 3
“…particularly in Kenya, Vietnam, and Indonesia, contribute to inconsistent adherence across departments and suboptimal prescribing practices, as highlighted in literature [27–29] Regular training and feedback mechanisms should be established to reinforce ASP principles and best practices.”
Implementation of a One Health Surveillance System in the Democratic Republic of the Congo
Kinzie, P. R., Lombe, B. P., Merritt, S., Halbrook, M., Vakaniaki, E. H., Mukadi, P., L’k’ye, A. M., Mona, J., Kanonge, D., Mfwangkang, M., et al. (2026) · EcoHealth · doi:10.1007/s10393-026-01802-9 · Cited by 2
Koroma, A. T. (2023) · Texila international journal of public health · doi:10.21522/tijph.2013.11.03.art022 · Cited by 3
Strengthening antimicrobial resistance surveillance across African military settings
Adebisi, Y. A. (2025) · International Health · doi:10.1093/inthealth/ihaf102 · Cited by 2
Isaac, E. W., Jalo, I., Manga, M. M., Difa, J. A., Poksireni, M. R., Christianah, O., Mohammed, I., & Charanci, M. S. (2022) · Open Journal of Medical Microbiology · doi:10.4236/ojmm.2022.124016 · Cited by 2
Kamara, I. F., Tengbe, S. M., Abu, P. M., Hailu, B., Madisa, T. M., Fofanah, B. D., Kargbo, F. B., Mansaray, B., Thekkur, P., Mustapha, M., et al. (2025) · BMC Public Health · doi:10.1186/s12889-025-25223-5 · Cited by 2
Jepleting, M., Mutai, W. C., Musyoki, V. M., Oduor, B., Ayodo, C., Mugoh, R., Kariuki, S., & Omulo, S. (2023) · Advances in Microbiology · doi:10.4236/aim.2023.134011 · Cited by 2
Self-citationMohamed, M. A., Tahlil, A. A., Osman, M. M., Gedi, S., Ali, B., Muhumed, M. B., Mohamed, A. A., Fiidow, O. A., Abatcha, M. G., Osman, A. Y., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3473448/v1 · Cited by 2
Harnessing Machine Learning for Antimicrobial Resistance Surveillance in ZimbabwePreprint
Mutahwa, L., Takawira, H. T., Muteveri, T., Watambwa, P., Chikobvu, D., Sengweni, W., Siyamayambo, C., Kasiroori, J., Chaka, L., & Mlambo, F. F. (2025) · Research Square · doi:10.1101/2025.09.02.25334969 · Cited by 2
“Pervasive poverty impacting adherence to expensive medications, frail health systems, and sometimes uncontrolled antibiotic dispensing has fostered conditions conducive to the rapid spread of resistance (Kariuki et al ., 2022; Gulumbe et al ., 2022).”
Antibiotic resistance of coliform bacteria in marine water and bivalve from Zanzibar Island
Khamis, M. A., Massawe, J. I., Mpinda, C. B., & Mpenda, F. N. (2025) · Discover Bacteria. · doi:10.1007/s44351-025-00023-9 · Cited by 1
“In developing countries, the increase in infections is due to limited access to essential medicines, limited diagnostic facilities, and insufficient infection prevention and control practices [3].”
Ahmad, A. O., Abayomi, M. A., Tony-Okpalaobi, O. H., Odetola, F. O., Njoku, O., Edebeatu, N. U., Oluwatosin, A. B., Oluchukwu, V. U., & Antai, D. A. (2025) · Epidemiology and Health Data Insights · doi:10.63946/ehdi/17210 · Cited by 2
“Meanwhile, limited healthcare and laboratory infrastructure mean that only about 1.3% of laboratories in 14 African countries can perform routine bacterial culture for AMR testing, which means that resistance often remains undetected and untreated (15, 16).”
InfluentialAli, V. E., Uketeh, S. N., Hamza, A., Obiajulu, I., Okeke, S. U., Asika, M. O., Obong, A. E., Aminu, H. Y., Ominyi, J., & Eze, U. A. (2025) · Discover Public Health · doi:10.1186/s12982-025-01047-x · Cited by 1
“West sub-Saharan Africa bears the greatest burden of AMR, with a mortality rate of 27.3 in every 100,000 deaths attributable to AMR [20].”
InfluentialAbubakari, A. W., Agbeko, R., Osei‐Adjei, G., & Kümmerli, R. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1696696 · Cited by 2
“In Ghana, ABR caused an estimated 5,900 direct deaths and contributed to 25,300 associated deaths in 2019, surpassing the mortality from many other public health challenges (Donkor et al., 2024; Kariuki et al., 2022; Donkor and Newman, 2011; Agyepong et al., 2018).”
Wubishet, M., Manahle, S., G/Meskel, T., Yinges, S. G., Agero, G., & Kebede, L. (2026) · PLoS ONE · doi:10.1371/journal.pone.0345245 · Cited by 4
“These data underscore an urgent need for strengthened antimicrobial stewardship and continuous resistance surveillance to safeguard effective neonatal sepsis management [68].”
Massir, I. N., Yacouba, A., Tapha, O., Hamidou, O., Ousmane, A., Ousmane, A., Moussa, H., Souleymane, B., Doutchi, M., SAIDOU, M., et al. (2026) · BMC Microbiology · doi:10.1186/s12866-026-05094-5 · Cited by 1
“…studies have documented the high prevalence and rapid dissemination of multidrug-resistant bacteria, including carbapenem-resistant Enterobacteriaceae, among vulnerable populations in sub-Saharan Africa, further compounding the burden of multidrug-resistant isolates in malnourished children [8, 9].”
Kimera, Z. I., & Matee, M. I. (2026) · Discover Public Health · doi:10.1186/s12982-026-02248-8 · Cited by 1
Shafaque, U., Ruckert, A., Orubu, E. S. F., Strong, K., Naro, S. G., Katwyk, S. R. V., & Poirier, M. J. P. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1875275 · Cited by 1
Pathogenic bacteria in air samples: an appraisal of the African studies versus other continents
Abegunde, M. O., Ogunlaja, O. O., Taylor, G. O., & Ogunlaja, A. (2025) · Aerobiologia · doi:10.1007/s10453-025-09859-9 · Cited by 1
“Reviews from Africa focusing on pathogenic bacteria mostly in human samples are common but environmental samples are rarely reported (Kariuki et al., 2022) and they follow the trend of water > soil > air samples (Abiola et al., 2018).”
Moradinazar, M., Gharib, K. H., Taherpour, M., & Jalilian, F. (2025) · Journal of Public Health · doi:10.1007/s10389-025-02560-8 · Cited by 1
Andrade, V. B., Fernandes, D. G. D. S., Almeida, D. V., da Cruz, G. F., Handajevsky, T. J., Ribeiro, D. A., Teixeira, C. S., da Silva, A. L. C., da Silva, F. D., & García, W. (2025) · ACS Omega · doi:10.1021/acsomega.5c03081 · Cited by 1
Gnimadi, T. A. C., Kadio, K. J. J. O., Camara, A., Hounmenou, C. G., Camara, S. C., Bangoura, S. T., Ogoumma, E. H., Kéita, A. K., Kaba, D., Camara, T., et al. (2025) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlaf223 · Cited by 1
Hedima, E. W., Joab, J., Otegwu, T. C., David, E. A., Kangla, A., & Labaran, K. S. (2025) · Discover Health Systems · doi:10.1007/s44250-025-00327-2 · Cited by 1
“Resistance to commonly used antibiotics such as ampicillin, cotrimoxazole, and tetracycline exceeds 75–80% in Ghana and Kenya [3–5].”
InfluentialDeterminants of pneumococcal carriage by age in Africa (2000–2021): a systematic analysis
Kwesi‐Maliepaard, E. M., Opoku, N. K.-D. O., Egyir, B., Dayie, N. T. K. D., Kusi, K. A., & Frimpong, A. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1683313 · Cited by 2
Munyemana, J. B., Nyishimente, N., Rutare, S., Nishimwe, A., Kundwa, Y., Manirakiza, D., Nkubana, T., Dusabe, A., & Ndayambaje, F. X. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1701316 · Cited by 1
“…year as a result of infections caused by antimicrobial-resistant pathogens, and AMR also contributes directly to the decline in the economy (19), where sub-Saharan Africa suffers the most with the highest mortality rate (23.5 deaths per 100,000) attributable to AMR compared to other regions (44).”
InfluentialSifuna, A. W., Wanjala, C. L., Mogoi, N. N., Olima, L., Malaba, R., Brealey, E., Mandillah, L., Njeru, F., Kindiki, S., Omedo, R., et al. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1731706 · Cited by 1
“This, in turn, has a negative clinical and cost implication for patients, communities and the healthcare system (10, 11).”
Omoniyei, L., Ibrahim, A. D., Odhiambo, J., Nsongurua, U., Babatunde, Y. O., Mawufemor, A. S., Francis, J., Ismail, S., Awolola, O., Hamza, H., et al. (2026) · BMC Medical Education · doi:10.1186/s12909-026-09015-y · Cited by 1
“This study focused on the pre-service curricula of five universities in SSA, a region with the highest AMR-attrib-utable mortality globally [27].”
Pathogenomics of multidrug-resistant Escherichia coli from bloodstream infections in South Africa
Hetsa, B. A., Yeboah, E. E. A., Ismail, A., Essack, S. Y., & Amoako, D. G. (2026) · BMC Medical Genomics · doi:10.1186/s12920-026-02349-y · Cited by 1
“In sub-Saharan Africa, recent studies highlight concerning rates of AMR among invasive E. coli isolates, underscoring the need for enhanced genomic surveillance across the region [5].”
Sambakunsi, H., Phiri, M., O’Byrne, T., Mankhomwa, J., Pongolani, R., Zaremba, J., Feasey, N., MacPherson, E. E., & Nyirenda, D. (2026) · PLOS Global Public Health · doi:10.1371/journal.pgph.0005697 · Cited by 1
“A recent review documented similar patterns across sSA, where structural health system challenges compound the AMR crisis [12].”
Agu, I. C., Agu, C. I., Obiobasi, C., Mbachu, C. O., King, R. A., Onwujekwe, O. E., & Das, M. (2026) · Discover Public Health · doi:10.1186/s12982-026-02079-7 · Cited by 1
Malesa, R. P., Pierneef, R., Magwedere, K., Mafuna, T., & Matle, I. (2026) · Genomics · doi:10.1016/j.ygeno.2026.111278 · Cited by 1
Majumdar, A., Johnson, D. R., & Kolb, S. (2026) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2026.143361 · Cited by 1
RetractedHayato, A., Meskel, T. G., & Tejineh, S. (2026) · BMC Pediatrics · doi:10.1186/s12887-026-07748-9 · Cited by 1
Impact of antimicrobial resistance on infections in children in Africa
Dame, J. A., Bockarie, Y. M., & Enimil, A. K. (2025) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000001440 · Cited by 2
Innovative Strategies for Reducing Antimicrobial Resistance: A Review of Global Policy and Practice
Kolawole, T. O., Mustapha, A. Y., Mbata, A. O., Tomoh, B. O., Forkuo, A. Y., & Kelvin-Agwu, M. C. (2025) · Journal of Frontiers in Multidisciplinary Research · doi:10.54660/.ijfmr.2025.6.1.80-93 · Cited by 1
Seid, M., Negash, W., Olani, A., Abera, S., & Nuru, A. (2025) · Discover Bacteria. · doi:10.1007/s44351-025-00030-w · Cited by 1
“Compared to other regions, sub-Saharan Africa had the greatest mortality rate (23.5 deaths per 100,000) due to antimicrobial resistance (AMR) in 2019 [9].”
InfluentialMusa, H. M., Odari, E. O., & Ochieng, J. B. (2025) · World s Veterinary Journal · doi:10.54203/scil.2025.wvj17 · Cited by 1
“According to the 2016 Global Burden of Disease (GBD) report, cumulatively, Diarrheagenic Escherichia coli (E. coli ), especially enteropathogenic E. coli (EPEC) and enterotoxigenic E. coli (ETEC) resulted in 63,523 deaths among all ages annually throughout the world (Kariuki et al., 2022).”
Mufungwe, J., Namukonde, N., Johnson, T., Siamujompa, M., Mwango, N. C., Ngoma, J., Mwaanga, P., & Hang’ombe, B. M. (2024) · Research Square · doi:10.21203/rs.3.rs-5053021/v1 · Cited by 1
Ganesan, B., Azuma, H., BAKER, R. C., Ferreira, J. P., & LeJeune, J. T. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.14.699574 · Cited by 1
Kiazolu, J. (2026) · Research Square · doi:10.21203/rs.3.rs-9876480/v1 · Cited by 1
Kyamulabi, M., Izudi, J., Mujugira, A., & Okoboi, S. (2023) · Research Square · doi:10.21203/rs.3.rs-3384287/v1
Ouédraogo, G. A., Sawadogo, A., Ouédraogo, A., Gnamou, A., Sanfo, S., Zonon, H., Diendéré, É. A., Savadogo, M., Diallo, I., & Sondo, A. K. (2024) · Asian Journal of Research in Infectious Diseases · doi:10.9734/ajrid/2024/v15i8366
Synergistic effects of Psidium guajava and procaine penicillin on MRSA, MSSA and E. faecalis
Nsele, N. W., Mathobela, K. P., Radebe, S. P., & Thembane, N. (2024) · Journal of Medicinal Plants for Economic Development · doi:10.4102/jomped.v8i1.268
“Scan this QR code with your smart phone or mobile device to read online. exacerbate its impact (Kariuki et al. 2022).”
BackgroundA Comprehensive Study on the Distribution of Integrons and Their Gene Cassettes in Clinical Isolates
Abdinia, F. S., Javadi, K., Rajabnia, R., & Ferdosi-Shahandashti, E. (2024) · DNA and Cell Biology · doi:10.1089/dna.2024.0175
Adeniji, O., Adesina, F., Adeniji, T., Olorunfemi, A., Adeoye, B., & Ojurongbe, O. D. (2024) · African Journal of Clinical and Experimental Microbiology · doi:10.4314/ajcem.v26i1.7 · Cited by 1
Nyaboke, E., Ogola, J. G., Okumu, M. O., Wasike, J., Naliaka, C., Lusweti, V., Anyanzwa, L., Kamau, P., Omesa, E., Kimani, T., et al. (2025) · Discover Public Health · doi:10.1186/s12982-025-00619-1
“Unfortunately, African countries, including Kenya, often lack sufficient data on antimicrobial use [23, 29, 34].”
Mwirigi, T. P., Songoro, E., Nyerere, A. K., Nzou, S. M., & Irekwa, R. M. (2025) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2025.136011
Mamkhize, M. S. R., Nsele, N. W., & Ghuman, S. (2025) · Student s Journal of Health Research Africa · doi:10.51168/sjhrafrica.v6i6.1869
Kokou, S., Abalo, M.-E. A. T., Kinde, R., Atekpe, S. P., Palanga, A. M., Lakougnon, B., Wasungu, D. B., Okotan, L., Bouraïma, Z., Douti, N., et al. (2025) · Journal of Interventional Epidemiology and Public Health · doi:10.37432/jieph-d-24-02070
Sub-Saharan medicinal plants and their medical use: a semi-systematic review
Akouya, A., Seid, A. B., Colizzi, V., Cappelli, G., & Campagna, D. (2025) · Sahelian Journal of Responsible One Health · doi:10.4081/sjroh.2025.535
Musa, S., Aliyu, S., Abdullahi, N. B., Khalid, H. L., Salihu, S. K., Dahiru, A. U., Muhammad, A. A., Abdullahi, K., Salisu, S., Gumbi, S. A., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2025-106612
“16 Thus, in West Africa, in 2019, antibiotic-resistant sepsis alone was responsible for 412 000–663 000 deaths.”
InfluentialPereira, A., Amaral, F., Coppo, M. J. C., Bailey, K. E., Ting, S., Gilkerson, J. R., Browning, G. F., Jong, J. B. D. C., & Toribio, J.-A. L. M. L. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1569037
Mayianda, J., Musyimi, D. M., & Muriira, N. G. (2025) · Archives of Ecotoxicology · doi:10.36547/ae.2025.7.3.66-78 · Cited by 1
Chizimu, J. Y., Mudenda, S., Daka, V., Mufwambi, W., Muhimba, Z., Yamba, K., Shawa, M., Mwangilwa, K., Hangoma, J. M., Fwoloshi, S., et al. (2025) · Antibiotics · doi:10.3390/antibiotics14111125 · Cited by 1
Rwigi, D., Nyerere, A. K., Diakhate, M. M., Kariuki, K. M., Tickell, K. D., Mutuma, T., Tornberg, S. N., Soge, O. O., Walson, J. L., Singa, B. O., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25678573
Self-citationRwigi, D., Nyerere, A. K., Diakhate, M. M., Kariuki, K. M., Tickell, K. D., Mutuma, T., Tornberg, S. N., Soge, O. O., Walson, J. L., Singa, B. O., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25678736
Self-citationGut microbiome and bacterial resistance to antibiotics: Reservoir or defence?
Vuković, D. (2025) · Medicinski podmladak · doi:10.5937/mp76-60542
Mugoh, R., Mutai, W. C., Musyoki, V. M., Ayodo, C., Oduor, B., Jepleting, M., Ita, T., Kiiru, S., & Omulo, S. (2025) · Pan African Medical Journal · doi:10.11604/pamj.2025.52.111.47901
“These findings align with observations from other studies that reported high resistance profiles in hospital settings [14,15], suggesting that selective pressure from antibiotic use within hospitals may play a significant role in shaping these resistance patterns.”
Pfaffendorf, C., Wicha, S. G., Petersen, E. L., May, J., Martens, M., Akenten, C. W., Mombo‐Ngoma, G., Kremsner, P. G., Dekker, D. M., Ramharter, M., et al. (2026) · Malaria Journal · doi:10.1186/s12936-025-05754-3
“Such adequate antibiotic stewardship would—at least theoretically—warrant safe and sustainable long-term use [27].”
Chigozie, V. U., Nnamani Monica, N., Igwe, K. N., & Ogbonna, B. O. (2026) · Journal of Communications In Healthcare · doi:10.1080/17538068.2026.2623348 · Cited by 1
Ullah, A., Ali, A., Nematullah, M., Singh, S. K., Paliwal, A. S., & Parveen, N. (2026) · iNew Medicine · doi:10.1002/inm3.70030
Nantanda, R., Najjingo, I., Kjærgaard, J., Reventlow, S., Ndekezi, D., Ssemata, A. S., & Østergaard, M. S. (2026) · npj Primary Care Respiratory Medicine · doi:10.1038/s41533-026-00493-7
“The inappropriate prescription of antibiotics by the HCWs, and the CGs frequent purchase of the same antibiotics over the counter is a vast problem, expensive for the CGs and society and contributing to the antibiotic resistance crisis 20 .”
Souhli, R. A., Ghorba, E. M. E., Kouchene, M. J., Arbai, M., Harrak, K. E., Chahid, N., Tahoune, H., & Rissoul, K. (2026) · Cureus · doi:10.7759/cureus.104524
Abegunde, M. O., Ademisoye, A. I., Abakpa, V. O., Ogunlaja, O. O., Olukanni, O. D., & Ogunlaja, A. (2026) · Aerobiologia · doi:10.1007/s10453-026-09910-3
Antimicrobial resistance in Burundi: a silent crisis
Akilimali, A., Shams, Z., Aborode, A. T., Alhassan, A., Langat, A. K., Wei, C. R., Isiko, I., Scott, G. Y., Kibukila, F., Karegeya, A., et al. (2026) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000004694
Healthcare associated infections and associated antimicrobial resistance in four African countries
Forrer, A., Kajumbula, H., Nyarko, E. O., Barasa, I. K., Osoo, M. O., Chagwira, A., Abangi, K., Abisai, R., Lozani, N., Ngoma, J., et al. (2026) · Wellcome Open Research · doi:10.12688/wellcomeopenres.25330.1
Metadata
- Authors
- Kariuki, S., Kering, K., Wairimu, C., Onsare, R., & Mbae, C.
- Affiliations
- Kenya Medical Research Institute (KE)
- Corresponding author
- Kariuki, Samuel
- Kering, Kelvin
- Wairimu, Celestine
- Mbae, Cecilia
- Venue
- Infection and Drug Resistance
- Publisher
- Informa UK Limited
- Published
- 2022-07
- Volume
- Volume 15
- Pages
- 3589-3609
- ISSN
- 1178-6973 (ISSN-L)
- PMC
- PMC9273632
- OpenAlex
- W4284678172
- Cited by
- 245
- References
- 189
- Citations by year
- 2026: 72 · 2025: 92 · 2024: 53 · 2023: 27 · 2022: 1
- FWCI
- 5.80
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Infection and Drug Resistance (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc-sa)
- Funders
- Wellcome Trust (215675/Z/19/Z)
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases (R01AI099525)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Life Sciences › Agricultural and Biological Sciences › Food Science › Salmonella and Campylobacter epidemiology
- Keywords
- antimicrobial resistance, antimicrobial resistance surveillance, sub-Saharan Africa, national action plans, One Health, antimicrobial stewardship, infection control, water, sanitation and hygiene, antimicrobial use regulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.